Celgene has been presented with a total of three trophies at the 2013 PMEA Awards, PMGroup's annual awards event honouring excellence in healthcare marketing and business practice.
The firm was awarded the prestigious title of small company of the year, thanks in large part to its work in expanding the availability and raising the profile of its multiple myeloma drug Revlimid, in partnership with patient organisation Myeloma UK.
“Celgene has picked up three accolades at the 2013 PMEA Awards, including the small company of the year prize.“
Celgene also won the rare diseases and orphan drugs award and the team of the year prize for its My Life Comes Before Myeloma campaign, which was conducted with the assistance of marketing agency Langland.
Its efforts have helped patients receive treatment earlier and for longer, offering significant benefits in controlling disease progression and improving survival.
The judging panel said: "As a company it collaborates effectively, internally and externally, achieving access for patients and delivering value for all."
Celgene is a multinational biopharmaceutical company that specialises in the treatment of various cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukaemia, non-Hodgkin's lymphoma and glioblastoma, as well as ovarian, pancreatic and prostate cancer.See all the latest jobs in Healthcare Communications